| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 67028 |
Intravitreal injection of a pharmacologic agent |
9,537 |
8,417 |
$1.07M |
| J0178 |
Injection, aflibercept, 1 mg |
1,274 |
1,233 |
$533K |
| 92134 |
|
16,036 |
15,726 |
$378K |
| J2778 |
Injection, ranibizumab, 0.1 mg |
876 |
848 |
$314K |
| J2777 |
Injection, faricimab-svoa, 0.1 mg |
537 |
537 |
$262K |
| 92012 |
Ophthalmological services: medical examination and evaluation, intermediate, established patient |
5,750 |
5,583 |
$232K |
| 92014 |
Ophthalmological services: medical examination and evaluation, comprehensive, established patient |
3,584 |
3,561 |
$133K |
| J9035 |
Injection, bevacizumab, 10 mg |
893 |
868 |
$55K |
| J7999 |
Compounded drug, not otherwise classified |
1,662 |
1,637 |
$30K |
| J3490 |
Unclassified drugs |
46 |
41 |
$22K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
381 |
381 |
$15K |
| 92226 |
|
1,429 |
840 |
$12K |
| Q5128 |
Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg |
27 |
27 |
$7K |
| 92202 |
|
910 |
908 |
$4K |
| 92225 |
|
252 |
132 |
$4K |
| 92004 |
Ophthalmological services: medical examination and evaluation, comprehensive, new patient |
91 |
91 |
$2K |
| 92250 |
|
83 |
81 |
$2K |
| 92201 |
|
79 |
79 |
$310.68 |